On World Ovarian Cancer Day, May 8, the Global Ovarian Cancer Research Consortium announces a second $1 million USD grant along with AWS compute support to power research that aims to improve ovarian cancer survival rates On World Ovarian Cancer Day the Global Ovarian Cancer Research Consortium, of which Ovarian Cancer Research Alliance (OCRA) is … Continued
Accelerating the Mission: OCRA President & CEO Audra Moran Named a Crain’s 2026 Notable Leader in Health Care Ovarian Cancer Research Alliance (OCRA) is proud to share that President and CEO Audra Moran has been named a Crain’s New York Business 2026 Notable Leader in Health Care—an annual recognition honoring executives whose leadership, innovation, and … Continued
Written by Julia Thayer, Associate Director, Advocacy FY2027 Budget Update & Advocacy Momentum As we continue through appropriations season, we wanted to share a quick update on the President’s proposed FY2027 budget and what it means for our community. While we’re still awaiting full details, there are a few key takeaways to highlight. A quick … Continued
Audra Moran, President and CEO of Ovarian Cancer Research Alliance (OCRA), has been recognized as a Crain’s New York Business 2026 Notable Leader in Health Care. Crain’s annual recognition spotlights health care executives whose leadership, innovation, and community commitment set a high bar for the field. Honorees are selected based on demonstrated impact, both within … Continued
This article was updated in April 2026 to reflect NCCN’s release of the 2026 Guidelines for Uterine Cancer Patients. OCRA is a proud sponsor of the 2026 Patient Guidelines for Cervical Cancer and Uterine Cancer, and the 2025 Patient Guidelines for Ovarian. We believe ensuring access to clear, understandable information is critical. NCCN provides wonderful … Continued
On March 25, 2026, the U.S. Food and Drug Administration (FDA) approved Lifyorli (relacorilant), made by Corcept Therapeutics, in combination with Abraxane (nab-paclitaxel) for adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior lines of treatment, including prior Avastin (bevacizumab). The approval follows last month’s FDA … Continued
OCRA’s Annual Advocacy Day Draws Survivors and Caregivers from Across the Country More than 120 gynecologic cancer survivors, caregivers, researchers and supporters from nearly forty states filled the halls of the U.S. Capitol on Tuesday, March 17—dressed in teal, the color of ovarian cancer awareness—as Ovarian Cancer Research Alliance (OCRA) held its annual Spring Advocacy Day. The … Continued
April is a full month at OCRA, with several new programs joining our ongoing lineup of workshops, educational sessions, and community events. Whether you’re looking for practical guidance, clinical information, or simply a chance to connect and create, there’s something here for you. New and Expanded Programs Advanced Care Planning Workshop Series April 6, 13, … Continued
Written by Julia Thayer, Associate Director, Advocacy This month, more than 120 OCRA Advocate Leaders traveled to Washington, DC for Advocacy Day—braving snowstorms, severe weather, and even a partial government shutdown to make their voices heard on Capitol Hill. We kicked things off with a full day of training, where the group built skills, shared stories, and … Continued
On March 17, 122 Advocate Leaders from nearly 40 states and Washington, DC, converged on Capitol Hill for OCRA’s Spring Advocacy Day. Together, they held 158 meetings with Congressional offices, carrying a clear message: Congress must sustain and build on its commitment to ovarian and gynecologic cancer research. The energy and reach of this year’s … Continued
On March 17, Ovarian Cancer Research Alliance (OCRA) Advocate Leaders from across the country will be on Capitol Hill for OCRA’s Spring Advocacy Day—and we need your voice, too. If you can’t join us in person, please take action to reinforce our efforts on the Hill and help us make a big impact. Advocacy Day Priorities This … Continued
Cool Hand Frank, a digital publication that spotlights nonprofits making a difference, has named Ovarian Cancer Research Alliance (OCRA) its featured cause for March 2026, spotlighting OCRA’s work in advancing ovarian and gynecologic cancer research and supporting patients and their loved ones. The publication cited a deeply personal connection to the cause, with the author … Continued
Get email updates about research news, action alerts, and ways to join the fight.
Our website uses cookies to ensure you get the best experience. By continuing to use this website, you indicate that you have read and agree to our Terms of Use and Privacy Policy.
